Cough News and Research

RSS

EMD Serono's L-BLP25 Phase III NSCLC trial does not meet primary endpoint

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).

19 Dec 2012

Alcohol and antibiotics: an interview with Dr Randall

Contrary to popular belief, there are only a handful of antibiotics that can interact with alcohol to cause unpleasant effects. The two main antibiotics you should definitely avoid drinking alcohol with are metronidazole (brand names include Flagyl) and tinidazole (brand names include Fasigyn).

18 Dec 2012

Ceramic cookstoves may not reduce risk of pneumonia in young rural Kenyan children

Inexpensive, locally-produced ceramic cookstoves may produce less smoke than traditional indoor 3-stone firepits, but they don't significantly reduce indoor air pollution or the risk of pneumonia in young children, according to results from a small, year-long observational study by researchers working in rural Kenya.

13 Dec 2012

Tiotropium benefits patients with chronic obstructive pulmonary disease

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide (tiotropium in brief) is one of the drugs available that can be prescribed for inhalation. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether tiotropium offers a perceptible advantage to patients compared to a dummy medication (placebo) and to other COPD drugs.

12 Dec 2012

Gestational age and size at birth affect risk of early diagnosis of esophagitis

Infants that are born preterm or with impaired growth have an increased risk of developing gastroesophageal reflux disease (GERD), possibly leaving them vulnerable to the development of esophageal adenocarcinoma later in life.

12 Dec 2012

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Forest Laboratories, Inc. and Almirall, S.A. announced today that Tudorza Pressair (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Belmora introduces mobile cough control application

Belmora LLC, makers of the FLANAX line of Over-The-Counter (OTC) health care products, announced the launch of a mobile cough control application.

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

Strengthen health systems to integrate polio vaccinations into routine childhood immunizations, Save the Children report says

Speaking at the GAVI Partners Forum in Dar es Salaam, Tanzania, David Olayemi, senior program adviser at Save the Children in Abuja, Nigeria, said fewer than half of children in Nigeria are receiving routine immunizations for diseases such as diphtheria, tetanus, and whooping cough (DTP), and the rate is dropping, Guardian health editor Sarah Boseley reports in her "Global Health Blog."

7 Dec 2012

Spine Revitalizer develops infographic about non-surgical back pain treatment

More than 3 in 4 Americans experience back pain at some point in their life. Thankfully, Spine Revitalizer has released a helpful resource to give basic information for those suffering from back pain.

6 Dec 2012

MSF expresses concerns regarding global vaccination efforts ahead of GAVI forum

"This week, the Global Alliance for Vaccines and Immunization (GAVI) is holding a forum in Dar es Salaam, Tanzania," Guardian health editor Sarah Boseley writes in her "Global Health Blog," noting, "Invited are 700 experts from all the organizations and countries GAVI works with, funding immunization programs across the globe and in some of the poorest places on the planet."

6 Dec 2012

WHO assists Middle East authorities with coronavirus investigation

The World Health Organization has sent a team to Jordan at the request of the country’s Ministry of Health to help investigate the emergence of a novel coronavirus that resulted in the deaths of two people earlier this year, and to assist with further epidemiologic surveillance.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season.

30 Nov 2012

Study: Tdap vaccination safe for seniors

A new study of the safety of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine supports the recommendation that those 65 and older get the vaccine to protect themselves and others, particularly young babies, from pertussis.

29 Nov 2012